Guardant Health (GH) Stock May Be 29% Undervalued Despite Higher Cash Burn

Guardant Health has been on a striking multi year run in the market, and that leaves a simple but important question for you as an investor. Is the current share price supported by the cash the business is expected to generate over time, once recent headlines and momentum are set aside?

• Guardant Health has delivered a very large gain over the past 3 years, which puts a lot of expectation into the price and makes the link back to its underlying cash generation especially important.
• Recent recognition for products like the Shield blood test and higher revenue expectations sit alongside a forecast of continued cash burn, which can affect how quickly the company’s operations may cover its spending needs.
• What if you looked at Guardant Health through its sales instead? See why Guardant Health's 16.0x P/S tells a different valuation story.

The issue now is whether Guardant Health’s current valuation is adequately explained by the cash flows implied by its Discounted Cash Flow (DCF) intrinsic value estimate.

If you want to stress test this same cash flow question beyond Guardant Health, compare it to 40 high quality undervalued stocks.

Does Guardant Health Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model used here projects the cash that Guardant Health might eventually return to shareholders and then discounts it back to today. Latest twelve month free cash flow is a loss of $226.1 million, so the whole framework relies on the idea that the business moves from cash drain to cash generation over the coming years.

Analyst and model estimates build in recovering and then growing free cash flow, with annual projections shifting from small outflows to sizeable positive figures through the 2030s. Those assumptions help explain why the DCF suggests an intrinsic value meaningfully above the current share price of $150.87, even though the company is not yet self funding. The recent forecast of higher full year cash burn helps explain why the market price has not fully reflected those longer term cash flow projections. Find out what Guardant Health could be worth using our Discounted Cash Flow (DCF) estimate.

The Guardant Health Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Guardant Health valuation puzzle leaves off by spelling out which combinations of future growth, profitability and earnings would need to occur for the stock to trade materially above or below today's level on the Community page. Rather than relying on a single multiple or one model output, each scenario lays out the key inputs behind its view of fair value so you can later compare those assumptions with the actual results the business reports.

One of the top narratives on Guardant Health: roughly fairly valued

This Narrative is the bearish analyst Narrative on Simply Wall St, built on the most pessimistic analyst price target and forecasts, not one person's view.

"The main thing that has to go right is that Guardant Health turns growing Shield and Reveal test volumes, broader payer coverage and improving COGS into sustained cash generation..."

Discover why this Narrative puts Guardant Health at roughly fairly valued.

The unanswered piece in the Guardant Health story

Guardant Health’s valuation is only one side of the puzzle, because Simply Wall St’s broader checks have flagged specific concerns that you may want to weigh for yourself before leaning on any model. Take a closer look at 2 warning signs (1 major) before settling on a valuation.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com